Hematologic Cancers | Data + Perspectives: Investigators Discuss the Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies in the Care of Patients with Hematologic Cancers
Research To Practice | Oncology Videos · Dr. Neil Love
September 1, 20221h 37m
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring perspectives from Drs Ajai Chari, Ian Flinn, Nikhil Munshi and Laurie Sehn, including the following topics:
- Part 1: Case Presentations and Clinical Decision-Making (0:00)
- Case: A man in his early 70s with diffuse large B-cell lymphoma (DLBCL) arising from follicular lymphoma — Ian W Flinn, MD, PhD (3:46)
- Case: A man in his late 50s with nongerminal center B-cell-like subtype DLBCL — Laurie H Sehn, MD, MPH (15:57)
- Case: CAR-T therapy during the pandemic — Nikhil C Munshi, MD (22:16)
- Case: Anti-BCMC bispecific in triple-class and penta-drug refractory disease — Ajai Chari, MD (33:54)
- CAR-T therapy for non-Hodgkin lymphoma — Dr Flinn (37:09)
- Bispecifics for non-Hodgkin lymphoma — Dr Sehn (51:48)
- CAR-T therapy for multiple myeloma — Dr Munshi (1:13:23)
- Bispecifics for multiple myeloma — Dr Chari (1:26:14)